LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Elizabeth C. Saunders"
  2. AU="Pratima Verma"
  3. AU="Nomaguchi, Masako"
  4. AU="Hutson, Alan D"
  5. AU="Jarvis, Deborah"
  6. AU="Yilmaz, Sevdican Ustun"
  7. AU="Kreisel, Wolfgang"
  8. AU="Tracy R. Nichols, Ph.D."
  9. AU="Hellal, Faycel"
  10. AU="Steffen Koschmieder"
  11. AU="Hsin-Hui Yu"
  12. AU="Watanabe, Sadanori"
  13. AU="Swarts, Benjamin M"
  14. AU="Zang, Trinity"
  15. AU="Almayahi, Basim A"
  16. AU="Lupke, Madeleine"
  17. AU="Tweed, Conor"

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Augmenting project ECHO for opioid use disorder with data-informed quality improvement

    Owen B. Murray / Marcy Doyle / Bethany M. McLeman / Lisa A. Marsch / Elizabeth C. Saunders / Katherine M. Cox / Delitha Watts / Jeanne Ryer

    Addiction Science & Clinical Practice, Vol 18, Iss 1, Pp 1-

    2023  Band 11

    Abstract: Abstract Background National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorder (MOUD; methadone, ... ...

    Abstract Abstract Background National opioid-related overdose fatalities totaled 650,000 from 1999 to 2021. Some of the highest rates occurred in New Hampshire, where 40% of the population lives rurally. Medications for opioid use disorder (MOUD; methadone, buprenorphine, and naltrexone) have demonstrated effectiveness in reducing opioid overdose and mortality. Methadone access barriers disproportionally impact rural areas and naltrexone uptake has been limited. Buprenorphine availability has increased and relaxed regulations reduces barriers in general medical settings common in rural areas. Barriers to prescribing buprenorphine include lack of confidence, inadequate training, and lack of access to experts. To address these barriers, learning collaboratives have trained clinics on best-practice performance data collection to inform quality improvement (QI). This project sought to explore the feasibility of training clinics to collect performance data and initiate QI alongside clinics’ participation in a Project ECHO virtual collaborative for buprenorphine providers. Methods Eighteen New Hampshire clinics participating in a Project ECHO were offered a supplemental project exploring the feasibility of performance data collection to inform QI targeting increased alignment with best practice. Feasibility was assessed descriptively, through each clinic’s participation in training sessions, data collection, and QI initiatives. An end-of-project survey was conducted to understand clinic staff perceptions of how useful and acceptable they found the program. Results Five of the eighteen health care clinics that participated in the Project ECHO joined the training project, four of which served rural communities in New Hampshire. All five clinics met the criteria for engagement, as each clinic attended at least one training session, submitted at least one month of performance data, and completed at least one QI initiative. Survey results showed that while clinic staff perceived the training and data collection to be useful, there ...
    Schlagwörter Primary care ; Medications for opioid use disorder ; Quality improvement ; Buprenorphine ; ECHO ; Medicine (General) ; R5-920 ; Social pathology. Social and public welfare. Criminology ; HV1-9960
    Thema/Rubrik (Code) 310
    Sprache Englisch
    Erscheinungsdatum 2023-04-01T00:00:00Z
    Verlag BMC
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: “It’s way more than just writing a prescription”

    Elizabeth C. Saunders / Sarah K. Moore / Olivia Walsh / Stephen A. Metcalf / Alan J. Budney / Patricia Cavazos-Rehg / Emily Scherer / Lisa A. Marsch

    Addiction Science & Clinical Practice, Vol 16, Iss 1, Pp 1-

    A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder

    2021  Band 16

    Abstract: Abstract Background Increasingly, treatment for opioid use disorder (OUD) is offered in integrated treatment models addressing both substance use and other health conditions within the same system. This often includes offering medications for OUD in ... ...

    Abstract Abstract Background Increasingly, treatment for opioid use disorder (OUD) is offered in integrated treatment models addressing both substance use and other health conditions within the same system. This often includes offering medications for OUD in general medical settings. It remains uncertain whether integrated OUD treatment models are preferred to non-integrated models, where treatment is provided within a distinct treatment system. This study aimed to explore preferences for integrated versus non-integrated treatment models among people with OUD and examine what factors may influence preferences. Methods This qualitative study recruited participants (n = 40) through Craigslist advertisements and flyers posted in treatment programs across the United States. Participants were 18 years of age or older and scored a two or higher on the heroin or opioid pain reliever sections of the Tobacco, Alcohol, Prescription Medications, and Other Substances (TAPS) Tool. Each participant completed a demographic survey and a telephone interview. The interviews were coded and content analyzed. Results While some participants preferred receiving OUD treatment from an integrated model in a general medical setting, the majority preferred non-integrated models. Some participants preferred integrated models in theory but expressed concerns about stigma and a lack of psychosocial services. Tradeoffs between integrated and non-integrated models were centered around patient values (desire for anonymity and personalization, fear of consequences), the characteristics of the provider and setting (convenience, perceived treatment effectiveness, access to services), and the patient-provider relationship (disclosure, trust, comfort, stigma). Conclusions Among this sample of primarily White adults, preferences for non-integrated versus integrated OUD treatment were mixed. Perceived benefits of integrated models included convenience, potential for treatment personalization, and opportunity to extend established relationships with medical ...
    Schlagwörter Patient preference ; Opioid use disorder ; Treatment model ; Integrated treatment ; Medicine (General) ; R5-920 ; Social pathology. Social and public welfare. Criminology ; HV1-9960
    Thema/Rubrik (Code) 150
    Sprache Englisch
    Erscheinungsdatum 2021-01-01T00:00:00Z
    Verlag BMC
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Towards detecting cocaine use using smartwatches in the NIDA clinical trials network

    August F. Holtyn / Eugene Bosworth / Lisa A. Marsch / Bethany McLeman / Andrea Meier / Elizabeth C. Saunders / Emre Ertin / Md Azim Ullah / Shahin Alan Samiei / Monowar Hossain / Santosh Kumar / Kenzie L. Preston / Massoud Vahabzadeh / Dikla Shmueli-Blumberg / Julia Collins / Jennifer McCormack / Udi E. Ghitza

    Contemporary Clinical Trials Communications, Vol 15, Iss , Pp - (2019)

    Design, rationale, and methodology

    2019  

    Abstract: Cocaine use in clinical trials is often measured via self-report, which can be inaccurate, or urine drug screens, which can be intrusive and burdensome. Devices that can automatically detect cocaine use and can be worn conveniently in daily life may ... ...

    Abstract Cocaine use in clinical trials is often measured via self-report, which can be inaccurate, or urine drug screens, which can be intrusive and burdensome. Devices that can automatically detect cocaine use and can be worn conveniently in daily life may provide several benefits. AutoSense is a wearable, physiological-monitoring suite that can detect cocaine use, but it may be limited as a method for monitoring cocaine use because it requires wearing a chestband with electrodes. This paper describes the design, rationale, and methodology of a project that seeks to build upon and extend previous work in the development of methods to detect cocaine use via wearable, unobtrusive mobile sensor technologies. To this end, a wrist-worn sensor suite (i.e., MotionSense HRV) will be developed and evaluated. Participants who use cocaine (N = 25) will be asked to wear MotionSense HRV and AutoSense for two weeks during waking hours. Drug use will be assessed via thrice-weekly urine drug screens and self-reports, and will be used to isolate periods of cocaine use that will be differentiated from other drug use. The present study will provide information on the feasibility and acceptability of using a wrist-worn device to detect cocaine use. Keywords: Cocaine, Device development, Mobile sensing, Methods or experimental design, Clinical trials network
    Schlagwörter Medicine (General) ; R5-920
    Sprache Englisch
    Erscheinungsdatum 2019-09-01T00:00:00Z
    Verlag Elsevier
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang